Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and marketing of products to treat human diseases. The Company’s focuses its efforts in four core therapeutic areas: central nervous system (CNS) disorders, pain, cancer and addiction. In addition to conducting an active research and development program, it markets seven products in the United States and number of products in countries throughout Europe. The Company’s principal product is PROVIGIL (modafinil) Tablets (C-IV), which comprised approximately 49% of its total consolidated net sales during the year ended December 31, 2007, of which approximately 94% was in the United States market. In June 2007, the Company announced that it has received approval from FDA to market NUVIGIL (armodafinil) Tablets (C- IV).
